Extended-release of Octreotide (LF-PB) for the Treatment of Seroma
Status:
Completed
Trial end date:
2016-07-19
Target enrollment:
Participant gender:
Summary
This is a multicentre, double blind, randomized placebo controlled trial to assess the effect
of LF-PB on seroma formation in women with breast cancer undergoing Axillary Lymph Node
Dissection (ALND).
Recruited patients will be randomly assigned to receive LF-PB 30 mg or placebo.